O. Ottmann

发表

Effects of recombinant human IL-7 on blast cell proliferation in acute lymphoblastic leukemia.

A. Ganser, O. Ottmann, D. Hoelzer, 1990, Leukemia.

D. Hoelzer, O. Ottmann, W. Hofmann, 1999, Leukemia.

TGFβ-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34+ cells from healthy donors, but not from patients with AML after MDS

W. Hofmann, S. Koschmieder, O. Ottmann, 2001, Leukemia.

Chromosomal organization and localization of the human histone deacetylase 5 gene (HDAC5).

W. Hiddemann, S. Schnittger, C. Schoch, 2000, Biochimica et biophysica acta.

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

W. Siegert, J. Lipton, D. Niederwieser, 2003, Leukemia.

Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation

H. Gschaidmeier, B. Wassmann, D. Hoelzer, 2001, Bone Marrow Transplantation.

A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphobla

H. Gschaidmeier, B. Wassmann, D. Hoelzer, 2003, Annals of Hematology.

Interleukin 3 and interleukin 3/gm‐csf combination therapy ‐ clinical implications

A. Ganser, O. Ottmann, D. Hoelzer, 1993, Stem cells.

Influence of human recombinant interferon-alpha and interferon-gamma on bone marrow progenitor cells of HIV-positive individuals.

A. Ganser, D. Hoelzer, M. Eder, 1992, AIDS research and human retroviruses.

Cytokine therapy for myelodysplastic syndrome

O. Ottmann, D. Hoelzer, O. Ottmann, 2000, Current opinion in hematology.

In vitro culture of common acute lymphoblastic leukemia blasts: effects of interleukin-3, interleukin-7, and accessory cells.

A. Ganser, D. Hoelzer, C. Bartram, 1992, Blood.

Effects of recombinant human interleukin-3 on human hematopoietic progenitor and precursor cells in vivo.

A. Ganser, O. Ottmann, D. Hoelzer, 1990, Blood.

Analysis of NUP98/NSD1 translocations in adult AML and MDS patients

K. Wagner, M. Heuser, F. Thol, 2013, Leukemia.

Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients

R. Schlenk, K. Götze, M. Lübbert, 2014, Leukemia.

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment

H. Gschaidmeier, O. Ottmann, B. Wassmann, 2003, Leukemia.

Effects of recombinant human interleukin-3 on human hematopoietic progenitor and precursor cells in vivo.

A. Ganser, O. Ottmann, D. Hoelzer, 1990, Blood.

Effect of recombinant human transforming growth factor beta and tumor necrosis factor alpha on bone marrow progenitor cells of HIV-infected persons

A. Ganser, O. Ottmann, D. Hoelzer, 1991, Annals of Hematology.

When the band begins to play: Histone acetylation caught in the crossfire of gene control

O. Ottmann, D. Hoelzer, O. Ottmann, 2000, Molecular carcinogenesis.

Current Status of Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor in the Management of Acute Lymphoblastic Leukemia

D. Hoelzer, O. Ottmann, 1997 .

Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib

H. Kantarjian, T. Smith, F. Giles, 2010, Clinical pharmacology and therapeutics.

Do G-CSF and GM-CSF contribute to the management of acute lymphoblastic leukemia?

D. Hoelzer, O. Ottmann, 1996, Leukemia.

Far-Western based protein-protein interaction screening of high-density protein filter arrays.

D. Hoelzer, O. Ottmann, U. Mahlknecht, 2001, Journal of biotechnology.

Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia

A. Ganser, O. Heidenreich, D. Hilfiker-Kleiner, 2013, Leukemia.

Regulation of early hematopoiesis in serum-deprived cultures of mafosfamide-treated and untreated CD34-enriched bone marrow cells.

A. Ganser, D. Hoelzer, M. Eder, 1991, Experimental hematology.

MYELOKATHEXIS TREATED WITH RECOMBINANT HUMAN GRANULOCYTE‐MACROPHAGE COLONY‐STIMULATING FACTOR (rhGM‐CSF)

A. Ganser, O. Ottmann, D. Hoelzer, 1992, British journal of haematology.

Rho family small GTPases control migration of hematopoietic progenitor cells into multicellular spheroids of bone marrow stroma cells

R. Henschler, T. Rossmanith, M. Kreutz, 2002, Journal of leukocyte biology.

Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?

D. Hoelzer, O. Ottmann, W. Hofmann, 1999, Leukemia.

Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin

W. Hofmann, O. Ottmann, B. Wassmann, 1998, Annals of Hematology.

The German competence network ‘Acute and chronic leukemias’

W. Hiddemann, H. Döhner, A. Ganser, 2004, Leukemia.

Genomic Organization and Regulation of the Human Interleukin‐18 Gene

C. Miething, N. Koyama, O. Ottmann, 2000, Scandinavian journal of immunology.

Down-stream regions of the POZ-domain influence the interaction of the t(11;17)-associated PLZF/RARalpha fusion protein with the histone-deacetylase recruiting co-repressor complex.

S. Boehrer, A. Bianchini, C. Nervi, 2001, The hematology journal : the official journal of the European Haematology Association.

Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all‐trans retinoic acid and haemopoietic growth factors

A. Ganser, O. Ottmann, D. Hoelzer, 1995, British journal of haematology.

Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?

O. Ottmann, D. Hoelzer, O. Ottmann, 1999, Leukemia.

Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)

M. Lübbert, H. Gschaidmeier, O. Ottmann, 2003, Leukemia.

Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor

A. Ganser, W. Hofmann, K. Höffken, 1999, Annals of Hematology.

Assignment1 of the human histone deacetylase 6 gene (HDAC6) to X chromosome p11.23 by in situ hybridization

W. Hiddemann, S. Schnittger, C. Schoch, 2001, Cytogenetic and Genome Research.

Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, in healthy subjects and patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed/refractory Ph+ acute lymphocytic leukemia (Ph+ALL).

K. Bhalla, H. Kantarjian, T. Smith, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation

H. Gschaidmeier, C. Thiede, A. Hochhaus, 2003, Bone Marrow Transplantation.

Imatinib for relapsed BCR/ABL positive leukemias.

B. Wassmann, D. Hoelzer, O. Ottmann, 2002, Annals of hematology.